张雪莹, 秦环龙. 肿瘤免疫治疗与肠道菌群关系的研究进展[J]. 上海预防医学, 2019, 31(10): 817-823. DOI: 10.19428/j.cnki.sjpm.2019.19539
引用本文: 张雪莹, 秦环龙. 肿瘤免疫治疗与肠道菌群关系的研究进展[J]. 上海预防医学, 2019, 31(10): 817-823. DOI: 10.19428/j.cnki.sjpm.2019.19539
ZHANG Xue-ying, QIN Huan-long. Research advances in relationship between tumor immunotherapy and gut microbiota[J]. Shanghai Journal of Preventive Medicine, 2019, 31(10): 817-823. DOI: 10.19428/j.cnki.sjpm.2019.19539
Citation: ZHANG Xue-ying, QIN Huan-long. Research advances in relationship between tumor immunotherapy and gut microbiota[J]. Shanghai Journal of Preventive Medicine, 2019, 31(10): 817-823. DOI: 10.19428/j.cnki.sjpm.2019.19539

肿瘤免疫治疗与肠道菌群关系的研究进展

Research advances in relationship between tumor immunotherapy and gut microbiota

  • 摘要: 肿瘤免疫治疗是继手术、化疗、放疗之后的肿瘤第四大疗法。肠道菌群对免疫检查点抑制剂和过继性T细胞治疗的抗肿瘤效果及免疫相关并发症的发生均有影响,其机制主要与肠道菌群调控“免疫激活-免疫耐受”平衡有关。特异性菌株的存在可作为预测免疫治疗的生物标记物,相关菌群制剂以及菌群移植等肠道菌群干预方式有望成为肿瘤免疫治疗的辅助手段。深入阐明肠道菌群影响免疫治疗的机制以及作为免疫增强剂的可行性、安全性和有效性,最终针对不同肿瘤患者制定个性化方案是未来研究的方向。

     

    Abstract: Tumor immunotherapy is the fourth major treatment for cancer, following surgery, chemotherapy and radiotherapy.Gut microbiota affects the anti-tumor effect and immune-related complications of immune checkpoint inhibitors and adoptive T-cell therapy, which is mainly related to the activation and balance regulation of the immune system.Specific strains can be used as a biomarker for predicting the outcome, and the intervention of gut microbiome such as bacterial agents and fecal microbiota transplantation are expected to become adjuvant therapies.In-depth clarification of the mechanism of gut microbiota affecting immunotherapy and its feasibility, safety and effectiveness as an immunopotentiator, and finally the development of personalized programs for different cancer patients is the direction of future research.

     

/

返回文章
返回